AR and Cachexia: As both AR silencing and excessive activation are associated with toxicity [53, 60], this study supports the development of treatments able to fine-tune AR-SMAD4 transcriptional cooperativity as a promising target for SBMA, cachexia and other conditions associated with muscle loss.